Data refreshed: 2026-03-14 PT from ClinicalTrials.gov
| Metric |
Value |
| Total Clinical Trials |
34 |
| Active Trials (Recruiting/Active) |
9 (26%) |
| Phase 1 Trials |
7 |
| Phase 2 Trials |
2 |
| Phase 3 Trials |
0 |
Adult Neurogenesis Therapeutics represents an emerging investment area focused on stimulating the brain's natural ability to generate new neurons to treat neurodegenerative diseases. This investment landscape analyzes funding trends, key companies, clinical trials, and opportunities in this field.
Adult neurogenesis - the production of new neurons in the adult brain - occurs primarily in two regions: the subventricular zone (SVZ) lining the ventricles and the subgranular zone (SGZ) of the dentate gyrus in the hippocampus. This capacity diminishes with age and is impaired in neurodegenerative diseases, making restoration of neurogenesis a compelling therapeutic approach.
- Cognitive function: New neurons integrate into hippocampal circuits supporting memory
- Disease modification: Replace lost neurons rather than just symptomatic treatment
- Combination potential: Works with other approaches (anti-amyloid, neuroprotection)
- Survival: Most new neurons die within weeks of birth
- Integration: Functional circuit integration is challenging
- Delivery: Getting cells or drugs to appropriate brain regions
- Timing: When in disease progression is intervention most effective?
The adult neurogenesis therapeutics field has attracted increasing investment interest from venture capital and pharmaceutical companies:
- Venture Capital: Active investment in stem cell therapy companies and neural regeneration startups
- Pharma Partnerships: Major pharmaceutical companies partnering with academic labs and biotech
- Government Funding: NIH and EU grants supporting neural stem cell research
¶ Key Companies and Programs
| Company |
Program |
Phase |
Mechanism |
| Neuralstem |
NSI-189 |
Phase 2 |
Neural stem cell therapy |
| Lundbeck |
Lu AF20513 |
Phase 1 |
Immunotherapy targeting Aβ |
| Cyto Therapeutics |
— |
Preclinical |
Neural stem cell encapsulation |
- StemoniX: iPSC-derived neural cells for drug screening
- Neuron梯: Neural stem cell therapy for PD
- Aspen Neuroscience: Autologous neuron replacement
- Embryonic stem cell-derived: Allogeneic neural progenitors
- iPSC-derived: Patient-specific, autologous therapy
- Adult neural stem cells: Patient's own NSCs
- NSI-189: Phenylpyridine analog promoting neurogenesis
- Antidepressants: SSRIs shown to enhance neurogenesis
- Exercise mimetics: BDNF-boosting compounds
- BDNF delivery: Neurotrophic factor expression
- Notch pathway modulation: Stem cell fate programming
- Large-scale manufacturing: Scalable stem cell production
- Delivery technologies: Targeted brain region injection
- Combination approaches: Neurogenesis + other mechanisms
- Biomarkers: Neural progenitor cell markers in humans
- Patient selection: Genetic/disease stage predictors of response
- Autologous iPSC-derived neuron therapy
- Small molecule neurogenesis enhancers
- Biomarker development for patient selection
- Brain-penetrant neurotrophic factors
Adult neurogenesis therapeutics represent a long-term bet on neural regeneration. While no late-stage programs exist yet, the fundamental biology provides a compelling rationale. Key to success will be:
- Demonstrating functional integration of new neurons
- Safe and scalable cell manufacturing
- Optimal patient selection